As Elon Musk moves to shutter the U.S. Agency for International Development, the agency’s support for the discovery of novel ...

Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $89 and keeps a Buy rating on the ...

In a report released today, Joon Lee from Truist Financial maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report). The company’s shares closed yesterday at $7.16. Leverage the ...

Under the terms of the agreement, TG Therapeutics obtains non-exclusive research, clinical and commercial rights to use MaxCyte's Flow Electroporation ® technology and ExPERT ™ platform.

RESEARCH TRIANGLE PARK, N.C., Feb. 14, 2025 /PRNewswire/ -- Dignify Therapeutics, a biotechnology company dedicated to restoring voluntary bowel and bladder function in patients with neurological ...

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S ...

President Donald Trump’s national security adviser on Wednesday sidelined about 160 National Security Council aides, sending them home while the administration reviews staffing and tries to ...

Freight transportation company Norfolk Southern (NYSE:NSC) will be reporting earnings tomorrow before the bell. Here’s what to expect. Norfolk Southern Corporation missed analysts’ revenue ...

On Monday, H.C. Wainwright downgraded Pliant Therapeutics (NASDAQ:PLRX) stock from Buy to Neutral following concerns about the safety of the company's lead drug candidate, bexotegrast. The stock ...

Image Source : AP/FILE PHOTO President Donald Trump speaks at a ball after his inauguration. National Security Adviser Mike Waltz has sidelined about 160 career government employees temporarily ...

SAN DIEGO — Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of off-the-shelf neuron replacement therapies for ...

TransCode Therapeutics (RNAZ) shares are rising after dosing the first patient in Cohort 3 of its Phase 1 trial for lead candidate TTX-MC138 No significant safety issues were reported in previous ...